Ads
related to: maker of zocor and fosamax free printable download 2023 calendar
Search results
Results From The WOW.Com Content Network
Fosamax Postmenopausal osteoporosis Merck: $1,552.7 $3,049 $3,134.4 $3,191.2 $3,159.7 sitagliptin: Januvia Type 2 diabetes Merck: $1,397.1 $667.5 $42.9 simvastatin: Zocor Reduction of LDL cholesterol Merck: $660.1 $876.5 $2,802.7 $4,381.7 $5,196.5 rizatriptan benzoate: Maxalt Migraine pain Merck: $529.2 $467.3 $406.4 $348.4 $309.9 finasteride ...
Alendronic acid/colecalciferol, sold under the brand name Fosamax Plus D among others, is a medication for the treatment of osteoporosis in men or in postmenopausal women. [ 3 ] [ 2 ] [ 4 ] [ 6 ] Alendronic acid/colecalciferol was approved for use in the United States and in the European Union in 2005.
Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. [4] It is taken by mouth. [ 4 ] Use is often recommended together with vitamin D , calcium supplementation , and lifestyle changes.
The company's 2023 research and development focus has been reported to be on drugs in the obesity, diabetes, Alzheimer's and autoimmune areas. [146] In July 2023, Lilly announced it would acquire Versanis for $1.93 billion. [147] In October 2023, Eli Lilly acquired Point Biopharma for $1.4 billion. [148]
Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. [4] It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. [4] It is also used to decrease the risk of heart problems in those at high risk. [4] It is taken by mouth. [4]
In April 2023, Merck announced it would acquire Prometheus Biosciences Inc for $10.8 billion. [144] In December 2023, Merck announced it had partnered with Owkin to develop artificial intelligence-powered digital pathology diagnostics that could be used to identify patients suitable for immunotherapies. The aim is to come up with tools that can ...
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
It is an official journal of the International Osteoporosis Foundation and the National Osteoporosis Foundation. [3] The journal is published monthly and includes original research on all areas of osteoporosis and its related fields, alongside reviews, educational articles, and case reports. The co-editors-in-chief are J.A. Kanis and F. Cosman.